JP2021529821A5 - - Google Patents
Info
- Publication number
- JP2021529821A5 JP2021529821A5 JP2021502435A JP2021502435A JP2021529821A5 JP 2021529821 A5 JP2021529821 A5 JP 2021529821A5 JP 2021502435 A JP2021502435 A JP 2021502435A JP 2021502435 A JP2021502435 A JP 2021502435A JP 2021529821 A5 JP2021529821 A5 JP 2021529821A5
- Authority
- JP
- Japan
- Prior art keywords
- immunoglobulin
- gene therapy
- aav
- vector
- polypeptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024051529A JP2024075765A (ja) | 2018-07-17 | 2024-03-27 | イムノグロブリンを除去又は減少させるための遺伝子治療ベクターの形質導入を増加または増強するための組成物および方法 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18305971 | 2018-07-17 | ||
| EP18305971.6 | 2018-07-17 | ||
| US201862768731P | 2018-11-16 | 2018-11-16 | |
| US62/768,731 | 2018-11-16 | ||
| PCT/EP2019/069280 WO2020016318A1 (en) | 2018-07-17 | 2019-07-17 | Compositions and methods for increasing or enhancing transduction of gene therapy vectors and for removing or reducing immunoglobulins |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024051529A Division JP2024075765A (ja) | 2018-07-17 | 2024-03-27 | イムノグロブリンを除去又は減少させるための遺伝子治療ベクターの形質導入を増加または増強するための組成物および方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021529821A JP2021529821A (ja) | 2021-11-04 |
| JP2021529821A5 true JP2021529821A5 (https=) | 2022-05-13 |
Family
ID=67303476
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021502435A Pending JP2021529821A (ja) | 2018-07-17 | 2019-07-17 | イムノグロブリンを除去又は減少させるための遺伝子治療ベクターの形質導入を増加または増強するための組成物および方法 |
| JP2024051529A Pending JP2024075765A (ja) | 2018-07-17 | 2024-03-27 | イムノグロブリンを除去又は減少させるための遺伝子治療ベクターの形質導入を増加または増強するための組成物および方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024051529A Pending JP2024075765A (ja) | 2018-07-17 | 2024-03-27 | イムノグロブリンを除去又は減少させるための遺伝子治療ベクターの形質導入を増加または増強するための組成物および方法 |
Country Status (28)
| Country | Link |
|---|---|
| US (3) | US20210228738A1 (https=) |
| EP (2) | EP3768304B1 (https=) |
| JP (2) | JP2021529821A (https=) |
| KR (1) | KR20210042308A (https=) |
| CN (2) | CN112689515A (https=) |
| AU (2) | AU2019306121B2 (https=) |
| BR (1) | BR112021000807A8 (https=) |
| CA (1) | CA3106368A1 (https=) |
| CL (1) | CL2021000112A1 (https=) |
| CO (1) | CO2021000326A2 (https=) |
| DK (1) | DK3768304T3 (https=) |
| ES (1) | ES2935970T3 (https=) |
| FI (1) | FI3768304T3 (https=) |
| HR (1) | HRP20221542T1 (https=) |
| HU (1) | HUE060720T2 (https=) |
| IL (1) | IL280099A (https=) |
| LT (1) | LT3768304T (https=) |
| MX (1) | MX2021000580A (https=) |
| PE (1) | PE20211859A1 (https=) |
| PH (1) | PH12021550115A1 (https=) |
| PL (1) | PL3768304T3 (https=) |
| RS (1) | RS63878B1 (https=) |
| SG (1) | SG11202100306VA (https=) |
| SI (1) | SI3768304T1 (https=) |
| SM (1) | SMT202300005T1 (https=) |
| UA (1) | UA130604C2 (https=) |
| WO (1) | WO2020016318A1 (https=) |
| ZA (1) | ZA202100202B (https=) |
Families Citing this family (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TR201813067T4 (tr) | 2008-09-15 | 2018-09-21 | Uniqure Biopharma B V | Faktör IX polipeptit mutantı, bunun kullanımları ve bunu üretmeye yönelik bir yöntem. |
| GB201502305D0 (en) * | 2015-02-12 | 2015-04-01 | Hansa Medical Ab | Protein |
| US20210228738A1 (en) | 2017-07-17 | 2021-07-29 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Compositions and methods for increasing or enhancing transduction of gene therapy vectors and for removing or reducing immunoglobulins |
| EP3774852A1 (en) | 2018-04-03 | 2021-02-17 | Stridebio, Inc. | Antibody-evading virus vectors |
| AU2019247748A1 (en) | 2018-04-03 | 2020-10-08 | Ginkgo Bioworks, Inc. | Antibody-evading virus vectors |
| MX2020010465A (es) | 2018-04-03 | 2021-01-08 | Vectores de virus para direccionamiento a tejidos oftalmicos. | |
| TW202005978A (zh) | 2018-05-14 | 2020-02-01 | 美商拜奧馬林製藥公司 | 新穎肝靶向腺相關病毒載體 |
| US20200165608A1 (en) * | 2018-11-23 | 2020-05-28 | Florida State University Research Foundation, Inc. | Inhibition of vascular endothelial cell-mediated phagocytic processes for treatment of demyelinating conditions |
| CA3127950A1 (en) * | 2019-01-28 | 2020-08-06 | Duke University | Compositions and methods for evading humoral immunity |
| CN114681472B (zh) * | 2019-03-13 | 2023-06-30 | 中国人民解放军军事科学院军事医学研究院 | 氨基葡萄糖及其衍生物作为抗病毒药物的应用 |
| AR118465A1 (es) | 2019-03-21 | 2021-10-06 | Stridebio Inc | Vectores de virus adenoasociados recombinantes |
| TW202104592A (zh) * | 2019-05-14 | 2021-02-01 | 美商拜奧馬林製藥公司 | 重複投予基因療法載體之方法 |
| WO2021067598A1 (en) | 2019-10-04 | 2021-04-08 | Ultragenyx Pharmaceutical Inc. | Methods for improved therapeutic use of recombinant aav |
| JP2022551739A (ja) | 2019-10-17 | 2022-12-13 | ストライドバイオ，インコーポレイテッド | ニーマン・ピック病ｃ型の治療のためのアデノ随伴ウイルスベクター |
| US12611436B2 (en) | 2019-10-17 | 2026-04-28 | Sarepta Therapeutics, Inc. | AAV transfer cassette |
| SG11202110968VA (en) | 2019-12-06 | 2021-10-28 | Regeneron Pharma | Anti-vegf protein compositions and methods for producing the same |
| KR20220133969A (ko) | 2020-01-28 | 2022-10-05 | 프리라인 테라퓨틱스 리미티드 | 바이러스 벡터에 대한 중화 항체 역가를 결정하기 위한 개선된 분석법 |
| JP2023514204A (ja) | 2020-02-14 | 2023-04-05 | ウルトラジェニックス ファーマシューティカル インコーポレイテッド | Ｃｄｋｌ５欠損障害を処置するための遺伝子治療 |
| AU2021268026A1 (en) | 2020-05-08 | 2023-01-19 | Regeneron Pharmaceuticals, Inc. | VEGF traps and mini-traps and methods for treating ocular disorders and cancer |
| CN111621506B (zh) * | 2020-05-09 | 2021-07-30 | 华中农业大学 | 牛支原体分泌蛋白MbovP0145及其应用 |
| GB202007431D0 (en) | 2020-05-19 | 2020-07-01 | Hansa Biopharma AB | Cysteine protease |
| EP4162951A4 (en) * | 2020-06-05 | 2024-07-10 | Shanghai Bao Pharmaceuticals Co., Ltd. | PHARMACEUTICAL COMPOSITION OF ENZYMES AND VIRUSES AND ASSOCIATED APPLICATION |
| WO2021254479A1 (zh) * | 2020-06-18 | 2021-12-23 | 上海宝济药业有限公司 | 一种免疫球蛋白降解酶IdeE的突变体 |
| RU2020122141A (ru) * | 2020-07-03 | 2022-01-04 | Максим Петрович Никитин | Способ и композиция на основе генотерапевтического агента и антитела, связывающегося с клетками крови |
| US20230265455A1 (en) * | 2020-07-29 | 2023-08-24 | University Of Florida Research Foundation, Incorporated | Improved aav-mediated x-linked retinoschisis therapies |
| AU2021328475A1 (en) | 2020-08-19 | 2023-03-16 | Sarepta Therapeutics, Inc. | Adeno-associated virus vectors for treatment of Rett syndrome |
| CN116710148A (zh) * | 2020-09-28 | 2023-09-05 | 斯克奥特比奥股份有限公司 | 组合物及其用途 |
| CA3195177A1 (en) | 2020-10-07 | 2022-04-14 | Asklepios Biopharmaceutical, Inc. | Therapeutic adeno-associated virus delivery of fukutin related protein (fkrp) for treating dystroglycanopathy disorders including limb girdle 2i (lgmd2i) |
| EP4304662A4 (en) * | 2021-03-08 | 2025-06-18 | The Regents of the University of California | Lentivirus protection via fc overexpression |
| WO2022192193A1 (en) * | 2021-03-09 | 2022-09-15 | The Board Of Regents Of The University Of Texas System | Methods and compositions for mutagenesis screening in mammalian cells |
| WO2022221529A1 (en) | 2021-04-16 | 2022-10-20 | Asklepios Biopharmaceutical, Inc. | Rational polyploid aav virions that cross the blood brain barrier and elicit reduced humoral response |
| WO2023280175A1 (en) * | 2021-07-06 | 2023-01-12 | National Institute Of Biological Sciences, Beijing | Methods for treating complex i deficiencies or cancers by modulating gro3p biosynthesis |
| US20250019721A1 (en) | 2021-08-11 | 2025-01-16 | Ultragenyx Pharmaceutical Inc. | Compositions and methods for treating a muscular dystrophy |
| EP4349365A1 (en) * | 2022-10-07 | 2024-04-10 | Hansa Biopharma AB | Co-treatment for gene therapy |
| CN115558021B (zh) * | 2022-12-01 | 2023-03-17 | 山东大学 | 一种转录因子、重组细胞及其在制备肿瘤治疗药物的应用 |
| CN116425873B (zh) * | 2023-06-02 | 2023-09-05 | 苏州百道医疗科技有限公司 | 一种抗ck6重组兔单克隆抗体及其应用 |
| CN117126270B (zh) * | 2023-10-25 | 2024-02-13 | 首都儿科研究所 | 一种2型人博卡病毒型别特异性抗体及其应用 |
| CN118217443B (zh) * | 2024-01-15 | 2026-04-03 | 国科温州研究院(温州生物材料与工程研究所) | 一种人发角蛋白止血海绵及其制备方法与应用 |
| WO2025155923A1 (en) | 2024-01-17 | 2025-07-24 | The Broad Institute, Inc. | Aav capsid modifications that enable improved cns-wide gene delivery through interactions with the transferrin receptor |
| WO2025217174A1 (en) | 2024-04-08 | 2025-10-16 | The Broad Institute, Inc. | Aav capsid modifications that enable improved cns-wide gene delivery through interactions with carbonic anhydrase iv |
| WO2025217163A2 (en) | 2024-04-08 | 2025-10-16 | The Broad Institute, Inc. | Novel aav capsids binding to human cd59 |
| WO2025256978A1 (en) | 2024-06-13 | 2025-12-18 | Bayer Aktiengesellschaft | Variants of igm and igg cleaving enzymes |
| WO2025256977A1 (en) | 2024-06-13 | 2025-12-18 | Bayer Aktiengesellschaft | Novel igm and igg cleaving enzymes |
| WO2026041758A1 (en) * | 2024-08-22 | 2026-02-26 | Genethon | Modified aav capsid with enhanced transduction efficiency |
| GB202414654D0 (en) | 2024-10-04 | 2024-11-20 | Hansa Biopharma AB | Regimen for vector-based therapies |
Family Cites Families (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US414A (en) | 1837-09-28 | Moetise-latch foe | ||
| US941A (en) | 1838-09-22 | Machine for sawing shingles and staves | ||
| US5139A (en) | 1847-06-05 | Cajsfkles | ||
| US5173A (en) | 1847-06-26 | Machinery for | ||
| US5139941A (en) | 1985-10-31 | 1992-08-18 | University Of Florida Research Foundation, Inc. | AAV transduction vectors |
| AU643427B2 (en) | 1988-10-31 | 1993-11-18 | Immunex Corporation | Interleukin-4 receptors |
| WO1991018982A1 (en) | 1990-06-05 | 1991-12-12 | Immunex Corporation | Type ii interleukin-1 receptors |
| AU8200191A (en) | 1990-07-09 | 1992-02-04 | United States of America, as represented by the Secretary, U.S. Department of Commerce, The | High efficiency packaging of mutant adeno-associated virus using amber suppressions |
| US5173414A (en) | 1990-10-30 | 1992-12-22 | Applied Immune Sciences, Inc. | Production of recombinant adeno-associated virus vectors |
| DE69233013T2 (de) | 1991-08-20 | 2004-03-04 | The Government Of The United States Of America As Represented By The Secretary Of National Institute Of Health, Office Of Technology Transfer | Adenovirus vermittelter gentransfer in den gastrointestinaltrakt |
| WO1995005864A1 (en) | 1993-08-27 | 1995-03-02 | Government Of The United States Of America, Represented By The Secretary Of The Department Of Health And Human Services | Convection-enhanced drug delivery |
| US5820873A (en) | 1994-09-30 | 1998-10-13 | The University Of British Columbia | Polyethylene glycol modified ceramide lipids and liposome uses thereof |
| US6074849A (en) | 1995-07-19 | 2000-06-13 | Genetics Institute, Inc. | Polynucleotides encoding human CTLA-8 related proteins |
| US6013516A (en) | 1995-10-06 | 2000-01-11 | The Salk Institute For Biological Studies | Vector and method of use for nucleic acid delivery to non-dividing cells |
| US6579520B2 (en) | 1998-05-15 | 2003-06-17 | Genentech, Inc. | IL-17 related mammalian cytokine polypeptides (IL-17E) |
| US6569645B2 (en) | 1999-05-14 | 2003-05-27 | Genentech, Inc. | IL-17 homologous polypeptides and therapeutic uses thereof |
| US5994136A (en) | 1997-12-12 | 1999-11-30 | Cell Genesys, Inc. | Method and means for producing high titer, safe, recombinant lentivirus vectors |
| EP1664316B1 (en) | 2003-09-15 | 2012-08-29 | Protiva Biotherapeutics Inc. | Polyethyleneglycol-modified lipid compounds and uses thereof |
| JP4764426B2 (ja) | 2004-06-07 | 2011-09-07 | プロチバ バイオセラピューティクス インコーポレイティッド | カチオン性脂質および使用方法 |
| PL1901773T3 (pl) * | 2005-06-09 | 2012-09-28 | Hansa Medical Ab | Zastosowanie proteinazy IDES (Z S. Pyogenes) do leczenia chorób autoimmunologicznych oraz odrzutów przeszczepu |
| CA2927045A1 (en) | 2006-10-03 | 2008-04-10 | Muthiah Manoharan | Lipid containing formulations |
| US7649243B2 (en) | 2006-11-06 | 2010-01-19 | International Business Machines Corporation | Semiconductor structures incorporating multiple crystallographic planes and methods for fabrication thereof |
| GB0624874D0 (en) | 2006-12-13 | 2007-01-24 | Hansa Medical Ab | Treatment |
| US20110177156A1 (en) | 2007-11-14 | 2011-07-21 | Szoka Jr Francis C | Sterol-Modified Amphiphilic Lipids |
| CA2740000C (en) | 2008-10-09 | 2017-12-12 | Tekmira Pharmaceuticals Corporation | Improved amino lipids and methods for the delivery of nucleic acids |
| CN111808084A (zh) | 2008-11-10 | 2020-10-23 | 阿布特斯生物制药公司 | 用于递送治疗剂的新型脂质和组合物 |
| US8722082B2 (en) | 2008-11-10 | 2014-05-13 | Tekmira Pharmaceuticals Corporation | Lipids and compositions for the delivery of therapeutics |
| US8569256B2 (en) | 2009-07-01 | 2013-10-29 | Protiva Biotherapeutics, Inc. | Cationic lipids and methods for the delivery of therapeutic agents |
| US9018187B2 (en) | 2009-07-01 | 2015-04-28 | Protiva Biotherapeutics, Inc. | Cationic lipids and methods for the delivery of therapeutic agents |
| US20130123338A1 (en) | 2010-05-12 | 2013-05-16 | Protiva Biotherapeutics, Inc. | Novel cationic lipids and methods of use thereof |
| WO2011141704A1 (en) | 2010-05-12 | 2011-11-17 | Protiva Biotherapeutics, Inc | Novel cyclic cationic lipids and methods of use |
| US8466122B2 (en) | 2010-09-17 | 2013-06-18 | Protiva Biotherapeutics, Inc. | Trialkyl cationic lipids and methods of use thereof |
| GB201103780D0 (en) | 2011-03-04 | 2011-04-20 | Hansa Medical Ab | Treatment for ige-mediated disease |
| ES2857773T5 (es) | 2011-08-24 | 2024-06-04 | Univ Leland Stanford Junior | Nuevas proteínas de la cápside de AAV para la transferencia de ácidos nucleicos |
| US9126966B2 (en) | 2011-08-31 | 2015-09-08 | Protiva Biotherapeutics, Inc. | Cationic lipids and methods of use thereof |
| GB201115841D0 (en) | 2011-09-13 | 2011-10-26 | Genovis Ab | Protein and method |
| GB201201314D0 (en) * | 2012-01-26 | 2012-03-07 | Isis Innovation | Composition |
| EP2817287B1 (en) | 2012-02-24 | 2018-10-03 | Arbutus Biopharma Corporation | Trialkyl cationic lipids and methods of use thereof |
| NZ701693A (en) | 2012-04-18 | 2017-02-24 | The Children’S Hospital Of Philadelphia | Composition and methods for highly efficient gene transfer using aav capsid variants |
| TWI698240B (zh) | 2012-05-15 | 2020-07-11 | 澳大利亞商艾佛蘭屈澳洲私營有限公司 | 使用腺相關病毒(aav)sflt-1治療老年性黃斑部退化(amd) |
| RU2625771C2 (ru) | 2012-05-23 | 2017-07-18 | Дженентек, Инк. | Способ отбора терапевтических средств |
| HK1222673A1 (zh) * | 2013-07-12 | 2017-07-07 | The Children's Hospital Of Philadelphia | Aav载体和用於抗aav(腺相关病毒)中和抗体的检测 |
| IL297919A (en) | 2013-07-22 | 2023-01-01 | Childrens Hospital Philadelphia | Variant aav and compositions, methods and uses for gene transfer to cells, organs and tissues |
| GB201413240D0 (en) | 2014-07-25 | 2014-09-10 | Hansa Medical Ab | Method |
| GB201502305D0 (en) * | 2015-02-12 | 2015-04-01 | Hansa Medical Ab | Protein |
| GB201502306D0 (en) | 2015-02-12 | 2015-04-01 | Hansa Medical Ab | Protein |
| SI3402491T1 (sl) * | 2016-01-11 | 2022-05-31 | Rubius Therapeutics, Inc. | Sestavki in postopki v zvezi z multimodalnimi terapevtskimi celičnimi sistemi za indikacije raka |
| AU2017214441B2 (en) | 2016-02-04 | 2021-08-19 | Genovis Ab | New Streptococcal proteases |
| WO2018093868A1 (en) | 2016-11-16 | 2018-05-24 | University Of Florida Research Foundation, Inc. | Immunoglobulin proteases, compositions, and uses thereof |
| WO2018109207A1 (en) | 2016-12-16 | 2018-06-21 | Uniqure Ip B.V. | Immunoadsorption |
| WO2018158397A1 (en) | 2017-03-02 | 2018-09-07 | Genethon | Method for removing anti-aav antibodies from a blood-derived composition |
| US20210228738A1 (en) | 2017-07-17 | 2021-07-29 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Compositions and methods for increasing or enhancing transduction of gene therapy vectors and for removing or reducing immunoglobulins |
-
2017
- 2017-07-17 US US17/050,911 patent/US20210228738A1/en not_active Abandoned
-
2019
- 2019-07-17 PL PL19740384.3T patent/PL3768304T3/pl unknown
- 2019-07-17 WO PCT/EP2019/069280 patent/WO2020016318A1/en not_active Ceased
- 2019-07-17 EP EP19740384.3A patent/EP3768304B1/en active Active
- 2019-07-17 CN CN201980048115.9A patent/CN112689515A/zh active Pending
- 2019-07-17 ES ES19740384T patent/ES2935970T3/es active Active
- 2019-07-17 HU HUE19740384A patent/HUE060720T2/hu unknown
- 2019-07-17 JP JP2021502435A patent/JP2021529821A/ja active Pending
- 2019-07-17 KR KR1020217001502A patent/KR20210042308A/ko not_active Ceased
- 2019-07-17 CN CN202411396316.7A patent/CN119345338A/zh active Pending
- 2019-07-17 DK DK19740384.3T patent/DK3768304T3/da active
- 2019-07-17 FI FIEP19740384.3T patent/FI3768304T3/fi active
- 2019-07-17 SG SG11202100306VA patent/SG11202100306VA/en unknown
- 2019-07-17 EP EP22198839.7A patent/EP4154904A1/en active Pending
- 2019-07-17 SM SM20230005T patent/SMT202300005T1/it unknown
- 2019-07-17 HR HRP20221542TT patent/HRP20221542T1/hr unknown
- 2019-07-17 BR BR112021000807A patent/BR112021000807A8/pt unknown
- 2019-07-17 RS RS20221191A patent/RS63878B1/sr unknown
- 2019-07-17 CA CA3106368A patent/CA3106368A1/en active Pending
- 2019-07-17 MX MX2021000580A patent/MX2021000580A/es unknown
- 2019-07-17 LT LTEPPCT/EP2019/069280T patent/LT3768304T/lt unknown
- 2019-07-17 SI SI201930426T patent/SI3768304T1/sl unknown
- 2019-07-17 PE PE2021000066A patent/PE20211859A1/es unknown
- 2019-07-17 UA UAA202100146A patent/UA130604C2/uk unknown
- 2019-07-17 AU AU2019306121A patent/AU2019306121B2/en active Active
-
2021
- 2021-01-11 IL IL280099A patent/IL280099A/en unknown
- 2021-01-12 ZA ZA2021/00202A patent/ZA202100202B/en unknown
- 2021-01-14 CL CL2021000112A patent/CL2021000112A1/es unknown
- 2021-01-15 CO CONC2021/0000326A patent/CO2021000326A2/es unknown
- 2021-01-15 PH PH12021550115A patent/PH12021550115A1/en unknown
- 2021-04-07 US US17/224,367 patent/US20210246469A1/en not_active Abandoned
-
2022
- 2022-07-12 US US17/862,622 patent/US20230142731A1/en active Pending
-
2024
- 2024-03-27 JP JP2024051529A patent/JP2024075765A/ja active Pending
-
2025
- 2025-08-13 AU AU2025217293A patent/AU2025217293A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021529821A5 (https=) | ||
| FI3768304T3 (fi) | Koostumuksia ja menetelmiä geeniterapiavektoreiden transduktion lisäämiseksi tai tehostamiseksi ja immunoglobuliinien poistamiseksi tai vähentämiseksi | |
| US20200231953A1 (en) | Compositions and methods for transient delivery of nucleases | |
| Luo et al. | Adeno-associated virus-mediated cancer gene therapy: current status | |
| JP2022121630A5 (https=) | ||
| JP2020528734A5 (https=) | ||
| JP2021512649A5 (https=) | ||
| JP2022531861A5 (https=) | ||
| RU2017125234A (ru) | Конструкции нуклеиновой кислоты и векторы для генотерапии для применения для лечения болезни вильсона и других состояний | |
| WO2023060269A4 (en) | Recombinant adeno-associated viruses for targeted delivery | |
| JP2023537625A5 (https=) | ||
| Xiao et al. | Recombinant adeno-associated virus: clinical application and development as a gene-therapy vector | |
| JP2021507687A5 (https=) | ||
| JP2021508241A5 (https=) | ||
| JP2019524090A5 (https=) | ||
| US20240102050A1 (en) | Compositions and methods for treatment of neurological disorders | |
| JP2021520811A5 (https=) | ||
| JP2024530023A5 (https=) | ||
| CN117821513A (zh) | 治疗退行性眼部疾病的药物组合物及方法 | |
| RU2019130004A (ru) | Генная терапия при глазных заболеваниях | |
| WO2024220719A1 (en) | Modified aav capsids for gene delivery | |
| US20230338582A1 (en) | Methods of Treating Human X-Linked Retinoschisis Using Gene Therapy | |
| US20240342314A1 (en) | Slc13a5 gene therapy vectors and uses thereof | |
| WO2024015877A9 (en) | Novel aav3b capsid variants with enhanced hepatocyte tropism | |
| KR20250114282A (ko) | 근육 특이적 조절 카세트 |